# Varsetatug masetecan

Source: https://onco.cc/drugs/varsetatug-masetecan/  
OnCo record `varsetatug-masetecan` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Varsetatug masetecan is an experimental masked antibody-drug conjugate from CytomX Therapeutics, in phase 1 trials for metastatic colorectal cancer.

## Summary

Varsetatug masetecan (CX-2051, Varseta-M) is a masked antibody-drug conjugate (Probody ADC, topoisomerase-1 inhibitor payload) from CytomX Therapeutics. A masked, conditionally activated antibody-drug conjugate directed at EpCAM that carries a topoisomerase-1 inhibitor payload. Its furthest stage is phase 1, for metastatic colorectal cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 dose expansion in colorectal cancer (NCT06265688); combination study NCT07900165 not yet recruiting. FDA Fast Track for relapsed/refractory metastatic colorectal cancer (27 August 2026). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: CX-2051; Varseta-M
- Tags: pipeline; ctgov-ingest
- Code: CX-2051
- Modality: Masked antibody-drug conjugate (Probody ADC, topoisomerase-1 inhibitor payload)
- Mechanism: A masked, conditionally activated antibody-drug conjugate directed at EpCAM that carries a topoisomerase-1 inhibitor payload.

## Sources

- CytomX Therapeutics: finviz.com: https://finviz.com/news/386131/cytomx-therapeutics-announces-fda-fast-track-designation-for-varsetatug-masetecan-varseta-m-for-relapsedrefractory-metastatic-colorectal-cancer-rr-mcrc
- CytomX Therapeutics: cytomx.com: https://cytomx.com/pipeline/
- ClinicalTrials.gov: trials of CX-2051: https://clinicaltrials.gov/search?intr=CX-2051

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [EpCAM](https://onco.cc/targets/epcam/)
- companies: [CytomX Therapeutics](https://onco.cc/companies/cytomx-therapeutics/)
- trials: [First In Human Study of CX-2051 in Advanced Solid Tumors](https://onco.cc/trials/nct06265688/), [Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer](https://onco.cc/trials/nct07900165/)

---
JSON: https://onco.cc/api/v1/entities/varsetatug-masetecan.json